In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist.
about
Addition of angiotensin II type 1 receptor blocker to CCR2 antagonist markedly attenuates crescentic glomerulonephritisOlmesartan medoxomil reverses glomerulosclerosis in renal tissue induced by myocardial infarction without changes in renal function.Role of olmesartan in combination therapy in blood pressure control and vascular function.Olmesartan medoxomil for the treatment of hypertension in children and adolescentsAngiotensinogen Expression Is Enhanced in the Progression of Glomerular Disease.Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertensionOlmesartan medoxomil: current status of its use in monotherapy.Effects of angiotensin II AT₁-receptor blockade on high fat diet-induced vascular oxidative stress and endothelial dysfunction in Dahl salt-sensitive rats.Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomilSevere Hyponatremia Associated with the Use of Angiotensin II Receptor Blocker/thiazide Combinations.Efficacy and Metabolic Influence on Blood-Glucose and Serum Lipid of Ziprasidone in the Treatment of Elderly Patients with First-Episode Schizophrenia.Renoprotective effects of telmisartan after unilateral renal ablation in rats.Hypertensive nephropathy treatment by heart-protecting musk pill: a study of anti-inflammatory therapy for target organ damage of hypertension.An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells.Olmesartan attenuates pressure-overload- or post-infarction-induced cardiac remodeling in mice.
P2860
Q28565493-1FD53006-CE44-43E0-ACEC-9B45AB7C8089Q33769695-D7AFFF7C-16AF-4AD0-B655-51503BD06ECBQ34139061-D6483154-F596-47ED-83BF-B621E53036F6Q34772915-734F13FF-5B6C-4ED5-A873-2C9565F15178Q35663915-B81CC7B6-5018-4E1F-9264-B98A4C7F8121Q36013049-4EF01D57-07BF-46E0-B06C-2548EC306D8CQ36013054-9D3395B0-CC5C-4B6F-9A6E-B1A8E246B202Q36630182-7408D179-7382-41EB-A6F0-3E766070E5CDQ37167510-CACEFF89-5AD4-4182-81CE-8DB7A29AE2EFQ37631017-ECD6CD27-EAEE-400C-B431-96853FC93A5BQ41066568-F82B7742-33EB-4940-B57D-0B43635F3A30Q42116074-0826A247-637A-4515-A518-C453FEAFBBE0Q42708271-67223911-3016-40B3-99E9-31DFC217A0D8Q43263326-CA4F6009-C69C-49B6-9B70-6E473EFA1A96Q54976930-C2892D80-CFFF-4FD4-A153-D2F4A75EDC70
P2860
In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
In vitro and in vivo pharmacol ...... type AT1 receptor antagonist.
@ast
In vitro and in vivo pharmacol ...... type AT1 receptor antagonist.
@en
In vitro and in vivo pharmacol ...... type AT1 receptor antagonist.
@nl
type
label
In vitro and in vivo pharmacol ...... type AT1 receptor antagonist.
@ast
In vitro and in vivo pharmacol ...... type AT1 receptor antagonist.
@en
In vitro and in vivo pharmacol ...... type AT1 receptor antagonist.
@nl
prefLabel
In vitro and in vivo pharmacol ...... type AT1 receptor antagonist.
@ast
In vitro and in vivo pharmacol ...... type AT1 receptor antagonist.
@en
In vitro and in vivo pharmacol ...... type AT1 receptor antagonist.
@nl
P2093
P1433
P1476
In vitro and in vivo pharmacol ...... type AT1 receptor antagonist.
@en
P2093
P577
2001-06-01T00:00:00Z